---
title: "INNOVITA's 7 respiratory antigen detection products have obtained medical device registration certification in Thailand"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/228715520.md"
description: "INNOVITA's respiratory antigen 7-item detection product (model: YF356C171) has recently obtained medical device registration certification from the Thai Food and Drug Administration, allowing it to be marketed in Thailand. This product can simultaneously detect 7 common pathogens, including the influenza A virus and the novel coronavirus, featuring efficiency, precision, and convenience, making it suitable for hospitals, laboratories, and grassroots health institutions"
datetime: "2025-02-18T14:46:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/228715520.md)
  - [en](https://longbridge.com/en/news/228715520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/228715520.md)
generator: "portal-rs"
---

# INNOVITA's 7 respiratory antigen detection products have obtained medical device registration certification in Thailand

Recently, the respiratory antigen 7-item testing product independently developed by INNOVITA successfully passed the medical device registration approval of the Thai Food and Drug Administration and was authorized for sale in the Thai market. The respiratory antigen 7-item testing product is an innovative in vitro diagnostic reagent that can simultaneously detect seven common pathogens, including influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus, adenovirus, and novel coronavirus. It features high efficiency, accuracy, and convenience, making it suitable for hospitals, laboratories, and grassroots health institutions

### Related Stocks

- [688253.CN](https://longbridge.com/en/quote/688253.CN.md)
- [M14.SG](https://longbridge.com/en/quote/M14.SG.md)

## Related News & Research

- [REG - Michael Hennigan Checkit PLC - Form 8.3 - Checkit plc](https://longbridge.com/en/news/298625777.md)
- [Fonn Group acquires Everviz & introduces Teikna](https://longbridge.com/en/news/298950768.md)
- [Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome](https://longbridge.com/en/news/299012192.md)
- [China’s Grandit Jumps on USD164 Million Plan to Boost Domestic High-Purity Quartz Supply](https://longbridge.com/en/news/298910479.md)
- [Teitur reports positive early data for Parkinson’s peptide TT‑P34](https://longbridge.com/en/news/298896579.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**